News >

Cemiplimab Explored in Advanced Basal Cell Carcinoma

Angelica Welch
Published: Friday, Nov 30, 2018

Dr Karl D. Lewis

Karl D. Lewis, MD
Patients with advanced basal cell carcinoma (BCC) who experience progression on or are intolerant to hedgehog pathway inhibitor therapy have no approved therapeutic options. An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab (Libtayo) in this population may prove efficacious based on its activity in other advanced malignancies.

Those enrolled on this phase II, nonrandomized, multicenter study will receive treatment until the end of the 93-week treatment period, until disease progression, unacceptable toxicity, withdrawal of concert, or confirmed complete response.
Lewis KD, Fury MG, Stankevich E, et al. Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy [published online October 29, 2018]. Ann Oncol. doi: 10.1093/annonc/mdy288.111.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication